🎈 Up Big Today: Find today's biggest gainers with our free screenerTry Stock Screener

RedHill wins $8 million judgment in New York court

Published 12/02/2024, 07:04 AM
© Redhill Biopharma PR
RDHL
-

TEL-AVIV, Israel and RALEIGH, N.C. - RedHill Biopharma Ltd. (NASDAQ: NASDAQ:RDHL), a specialty biopharmaceutical company with a current market capitalization of $10.88 million, has been awarded a judgment of approximately $8 million plus costs by the New York Supreme Court in a legal case against South Korea-based Kukbo Co. Ltd. The judgment, which includes $6.5 million plus about $1.5 million in interest, concludes a dispute over Kukbo's failure to fulfill payment obligations under a Subscription Agreement and an Exclusive License Agreement with RedHill.

The court dismissed all of Kukbo's counterclaims, affirming RedHill's adherence to the terms of the agreements. Dror Ben-Asher, CEO of RedHill, expressed gratitude for the court's decision and the legal representation provided by Haynes and Boone, LLP. Kukbo retains the right to appeal the judgment, and RedHill intends to pursue the collection of the awarded amount as well as its attorneys' fees.

RedHill Biopharma focuses on the commercialization and development of drugs for gastrointestinal diseases, infectious diseases, and oncology. The company markets Talicia® for the treatment of Helicobacter pylori infection in adults and has several late-stage development programs for other medical conditions.

This news follows a series of other developments for RedHill, including advancements in its clinical programs and commercial product launches. The company's recent success in court may further bolster its financial and operational stability.

This report is based on a press release statement from RedHill Biopharma.

In other recent news, RedHill Biopharma Ltd. has seen significant strides in various areas. The U.S. Biomedical Advanced Research and Development Authority (BARDA) has selected RedHill's opaganib for development funding as a potential Ebola virus disease treatment. The funding supports opaganib's development under the Animal Rule pathway, which allows for animal model efficacy studies to support FDA approval when human trials are not feasible. Opaganib has shown mutation-resistant antiviral and anti-inflammatory activity, and its development is part of a broader effort to address the need for medical countermeasures for Ebola and other potential biodefense threats.

Simultaneously, RedHill has renewed its contract with Medi-Cal, ensuring continued access to Talicia, a treatment for H. pylori infection, for roughly 15 million Californians. The renewal aligns with the new American College of Gastroenterology Clinical Guideline, which recommends Talicia as a first-line treatment. These are recent developments as the company continues to explore additional treatment options and enhance pandemic preparedness.

In financial developments, RedHill Biopharma has finalized a Global Termination Agreement, augmenting its cash position by approximately $9.9 million and potentially granting access to an additional $0.74 million. This agreement concludes credit relationships with Movantik Acquisition Co., Valinor Pharma, LLC, and HCR Redhill SPV, LLC, thereby enhancing RedHill's financial flexibility.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.